FDA approves trifluridine and tipiracil with bevacizumab for previously treated metastatic colorectal cancer

On August 2, 2023, the Food and Drug Administration (FDA) approved trifluridine and tipiracil (Lonsurf Taiho Oncology, Inc.) with bevacizumab, for metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.

FDA had previously approved single-agent Lonsurf for this indication in September 2015.

View full prescribing information for LONSURF